Zehan Pang

Zehan Pang

Auto-generated profile, based on publicly available information

Zehan Pang

College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2022 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
MLMaochen Li
Maochen Li
HWHan Wang
Han Wang
LTLili Tian
Lili Tian
ZPZehan Pang
Zehan Pang
QYQingkun Yang
Qingkun Yang
HFHuahao Fan
Huahao Fan
With the constantly mutating of SARS-CoV-2 and the emergence of Variants of Concern (VOC), the implementation of vaccination is critically important. Existing SARS-CoV-2 vaccines mainly include inactivated, live attenuated, viral vector, protein subunit, RNA, DNA, and virus-like particle (VLP) vaccines. Viral vector vaccines, protein subunit vaccines, and mRNA vaccines may induce additional cellular or humoral immune regulations, including Th cell responses and germinal center responses, and form relevant memory cells, greatly improving their efficiency. However, some viral vector or mRNA vaccines may be associated with complications like thrombocytopenia and myocarditis, raising concerns about the safety of these COVID-19 vaccines. Here, we systemically assess the safety and efficacy of COVID-19 vaccines, including the possible complications and different effects on pregnant women, the elderly, people with immune diseases and acquired immunodeficiency syndrome (AIDS), transplant recipients, and cancer patients. Based on the current analysis, governments and relevant agencies are recommended to continue to advance the vaccine immunization process. Simultaneously, special attention should be paid to the health status of the vaccines, timely treatment of complications, vaccine development, and ensuring the lives and health of patients. In addition, available measures such as mix-and-match vaccination, developing new vaccines like nanoparticle vaccines, and optimizing immune adjuvant to improve vaccine safety and efficacy could be considered.

10 December 2024 in Clinical Microbiology Reviews
Verified
Journal Article
Closed access
ZPZehan Pang
Zehan Pang
ATAo Tang
Ao Tang
YHYujie He
Yujie He
JFJunfen Fan
Junfen Fan
QYQingmao Yang
Qingmao Yang
HFHuahao Fan
Huahao Fan
SUMMARY: SARS-CoV-2 can not only cause respiratory symptoms but also lead to neurological complications. Research has shown that more than 30% of SARS-CoV-2 patients present neurologic symptoms during COVID-19 (A. Pezzini and A. Padovani, Nat Rev Neurol 16:636–644, 2020, https://doi.org/10.1038/s41582-020-0398-3 ). Increasing evidence suggests that SARS-CoV-2 can invade both the central nervous system (CNS) (M.S. Xydakis, M.W. Albers, E.H. Holbrook, et al. Lancet Neurol 20: 753–761, 2021 https://doi.org/10.1016/S1474-4422(21)00182-4 ) and the peripheral nervous system (PNS) (M.N. Soares, M. Eggelbusch, E. Naddaf, et al. J Cachexia Sarcopenia Muscle 13:11–22, 2022, https://doi.org/10.1002/jcsm.12896 ), resulting in a variety of neurological disorders. This review summarized the CNS complications caused by SARS-CoV-2 infection, including encephalopathy, neurodegenerative diseases, and delirium. Additionally, some PNS disorders such as skeletal muscle damage and inflammation, anosmia, smell or taste impairment, myasthenia gravis, Guillain-Barré syndrome, ICU-acquired weakness, and post-acute sequelae of COVID-19 were described. Furthermore, the mechanisms underlying SARS-CoV-2-induced neurological disorders were also discussed, including entering the brain through retrograde neuronal or hematogenous routes, disrupting the normal function of the CNS through cytokine storms, inducing cerebral ischemia or hypoxia, thus leading to neurological complications. Moreover, an overview of long-COVID-19 symptoms is provided, along with some recommendations for care and therapeutic approaches of COVID-19 patients experiencing neurological complications.

14 May 2024 in Analytica Chimica Acta
Verified
Journal Article
Closed access
YPYadan Peng
Yadan Peng
RHRuolan Hu
Ruolan Hu
SXShuang Xue
Shuang Xue
YHYugan He
Yugan He
LTLili Tian
Lili Tian
TYTong Yigang
Tong Yigang